EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Pharmacologic management after denosumab discontinuation in osteoporosis: A systematic review and meta-analysis

Rathapoom Suwanaratana, Attaporn Lawanprasert, Nuttawut Chanalithichai

Therapeutic Advances in Musculoskeletal Disease · 2026-08 · 18

DOI: 10.1177/1759720x261502297 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 29.10.2026. Verfasst von Rathapoom Suwanaratana und 2 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Denosumab discontinuation is associated with rebound bone turnover, rapid bone mineral density (BMD) loss, and increased vertebral fracture risk. Although subsequent antiresorptive therapy is recommended, the comparative effectiveness of post-denosumab strategies remains uncertain.

Objectives

To evaluate management strategies after denosumab discontinuation in adults treated for osteoporosis or low bone mass, with emphasis on vertebral fracture risk, BMD response, and bone turnover marker (BTM) patterns.

Design

Systematic review and meta-analysis. Data Sources and Methods PubMed/MEDLINE, Scopus, and the Cochrane Library/CENTRAL were searched through May 24, 2026. Eligible reports evaluated adults who discontinued, delayed, or transitioned from denosumab and reported fracture, BMD, or BTM outcomes after management. Comparative vertebral fracture data were pooled using random-effects risk ratios. Lumbar spine BMD change after zoledronate follow-on therapy was synthesized using supportive single-arm random-effects meta-analysis. Heterogeneous comparative BMD and BTM outcomes were summarized narratively.

Results

Twenty-two reports representing 19 studies or cohorts were included. Three comparative reports contributed to the vertebral fracture meta-analysis. More potent bisphosphonate follow-on therapy was associated with a lower vertebral fracture risk than no treatment or less potent antiresorptive therapy (pooled risk ratio 0.25, 95% CI 0.11 to 0.60; I 2 = 0%). In the strict single-arm zoledronate synthesis, the supportive pooled estimate of residual lumbar spine BMD change was −1.86% (95% CI −4.63 to 0.91; I 2 = 89.7%). Comparative BMD evidence generally suggested greater preservation with alendronate or zoledronate than with no treatment or other less potent antiresorptive strategies. BTM evidence showed heterogeneous post-transition turnover patterns, with persistent CTX elevation associated with residual BMD loss in some studies. However, marker-guided retreatment was not shown to improve clinical outcomes.

Conclusion

Very low-certainty evidence supports planned antiresorptive therapy after denosumab discontinuation rather than passive cessation. The available evidence does not establish a preferred agent or regimen, and optimal timing, dosing, and retreatment strategies remain uncertain.

Zitieren

APA

Suwanaratana, R., Lawanprasert, A., & Chanalithichai, N. (2026). Pharmacologic management after denosumab discontinuation in osteoporosis: A systematic review and meta-analysis. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261502297

Vancouver

Suwanaratana R, Lawanprasert A, Chanalithichai N. Pharmacologic management after denosumab discontinuation in osteoporosis: A systematic review and meta-analysis. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261502297

BibTeX
@article{Suwanaratana2026,
  author = {Suwanaratana, Rathapoom and Lawanprasert, Attaporn and Chanalithichai, Nuttawut},
  title = {Pharmacologic management after denosumab discontinuation in osteoporosis: A systematic review and meta-analysis},
  journal = {Therapeutic Advances in Musculoskeletal Disease},
  year = {2026},
  volume = {18},
  doi = {10.1177/1759720x261502297}
}
Kostenlos starten →